top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

83.66 -3.26 (-3.75%)
Streaming Delayed Price Updated: 12:28 PM EDT, Jun 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apogee Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot ↗
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot. 
Via Investor's Business Daily
News headline image
What's going on in today's pre-market session ↗
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
Top 2 Health Care Stocks That May Plunge This Month ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Apogee Therapeutics' Eczema Drug Provides Rapid Itch Relief In Phase 2 Trial ↗
Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B is ongoing. 
Via Benzinga
News headline image
Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
Webcast to be held Monday, July 7th at 8:00 a.m. ET 
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Why Is Apogee Therapeutics Stock Trading Higher On Monday? ↗
Apogee's APG808 cut key asthma biomarker FeNO by 53% at 12 weeks with no severe adverse events, showing potential for long-term maintenance dosing. 
Via Benzinga
News headline image
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
From Apogee Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial ↗
Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent. 
Via Benzinga
News headline image
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
Webcast to be held Monday, March 3rd at 8:30 a.m. ET 
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate in Upcoming March Investor Conferences
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Agenda for Virtual R&D Day
From Apogee Therapeutics
Via GlobeNewswire
News headline image
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatments 
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page